Full-Time

Investor Relations Manager

MicroVentures

MicroVentures

51-200 employees

Equity crowdfunding platform for startup investments

No salary listed

Austin, TX, USA

Hybrid

Must reside in or be willing to relocate to Austin, TX.

Category
Finance & Banking (1)
Requirements
  • 2-5 years of experience in managing a customer service team
  • Experience in the Financial Services industry, particularly in venture capital or private equity
  • Strong project management skills and ability to meet critical deadlines
  • Expertise in financial instruments, with a focus on private placements, venture capital, and private equity
  • Excellent communication skills (written and oral) and the ability to work effectively in a team environment
  • Experience with remote team management
  • Strong communication, organizational and project management skills
  • Hold the following Securities licenses: Series 7, Series 63 or 65
  • Hold or be willing to obtain a Series 24
  • Candidates must reside in or be willing to relocate to Austin, TX
Responsibilities
  • Supervise, manage, and expand the Investor Relations team
  • Oversee the training and development of staff to ensure high customer service standards
  • Manage a distributed team effectively, ensuring coverage across various time zones
  • Act as the primary liaison to the investor base
  • Deepen existing investor relationships and onboard new ones
  • Assist with onboarding new investors and manage client communication related to KYC, fundings, and distributions
  • Drive key metrics in revenue growth and new business development
  • Maintain workflow documentation, training, and manage technology enhancements for efficient sales operations
  • Manage client communications through various channels including chat, email, phone, and queues
  • Ensure the team meets internal and external goals and metrics
  • Maintain awareness of client money flows and related regulations

MicroVentures runs an equity crowdfunding platform within the fintech space. It lets both accredited and non-accredited investors invest in high-growth startups and private-market opportunities that were once only available to venture funds and institutions. The platform handles the investment process online and charges fees on both sides: investors incur fees based on their investment amount, while companies pay listing fees to run fundraising campaigns. It also provides educational resources to help investors understand equity crowdfunding risks. Compared with competitors, MicroVentures differentiates itself by enabling participation from non-accredited investors and by supporting a dual-fee model on the platform. The company’s goal is to connect a broad range of investors with early-stage opportunities in private markets and to facilitate funding for startups through its online marketplace.

Company Size

51-200

Company Stage

Seed

Total Funding

$1.5M

Headquarters

Austin, Texas

Founded

2009

Simplify Jobs

Simplify's Take

What believers are saying

  • Over $550M raised on platform since 2011 across 400+ companies.
  • Hybrid model provides Reg CF for non-accredited and Reg D for accredited investors.
  • Serves 60,000+ accredited investors including international participants.

What critics are saying

  • StartEngine and Wefunder fragment non-accredited investor base within 12-24 months.
  • 90% early-stage startup failures damage reputation and deter investors in 6-18 months.
  • SEC enforcement suspends operations and broker-dealer status in 18-36 months.

What makes MicroVentures unique

  • MicroVentures is the only major equity crowdfunding site registered as FINRA broker-dealer.
  • MicroVentures accepts less than 0.5% of startup applicants after rigorous due diligence.
  • MicroVentures offers investments starting at $100 for vetted startups since 2009.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

401(k) Company Match

Company Equity

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

2%
Yahoo Finance
Oct 4th, 2023
Mighty Buildings lands $22M to create 'sustainable and affordable' 3D-printed homes

Oakland-based Mighty Buildings, which is on a quest to build homes using 3D printing, robotics and automation, has raised a $22 million extension to its Series B round of funding. The company claims to be able to 3D print structures “two times as quickly with 95% less labor hours and 10-times less waste” than conventional construction. For example, it says it can 3D print a 350-square-foot studio apartment in just 24 hours.

News Direct
Jun 9th, 2023
BIOSAPIEN CLOSES $1.8M SEED ROUND LED BY SOSV & HIKMA VENTURES | News Direct

3D Printed Biodegradable Mesh Designed to Deliver Cancer Drugs Directly to Tumor Site With Greater Efficacy, Reduced Side Effects

Business Wire
Jun 9th, 2023
ICON, in one of the Largest Seed Rounds for Texas Start-Ups in 2018, Announces $9 Million in Funding

ICON, in one of the largest seed rounds for Texas start-ups in 2018, announces $9M in funding.

NewswireJet
Feb 13th, 2023
Pneumeric, Inc., Manufacturers of the CAPNOSPOT™ Medical Device, Announce Nearly $40,000 Raised from Its Equity Crowdfunding Campaign - NewswireJet

Rochester, MN | February 10, 2023 – Pneumeric Inc., developers of the Capnospot™ - A disposable medical device that allows visual detection of carbon dioxide during treatment of a collapsed lung with needle decompression, has raised nearly $40,000 from 124 investors through its recently launched equity crowdfunding campaign. These funds build on the $1.2 million Pneumeric has

PR Newswire
Aug 15th, 2022
Remedium Bio Announces Successful $2.3M Expanded Seed Raise

BOSTON, Aug. 15, 2022 /PRNewswire/ -- Remedium Bio, Inc., a biotechnology company developing novel gene therapies, today announced that it has closed more than $2.3M in its expanded seed round financing. Funding from the raise is being used to study Remedium's lead product, a single-injection gene therapy potentially capable of reversing cartilage loss, in a collaboration with Tufts University School of Medicine scientists researching rheumatic disorders. The financing was led by Sherwood Ventures and included participation from, LongevityTech.Fund, Primo Medical Group, Angel Star Ventures, Apis Health Angels, MicroVentures, and Guindy Alumni Angels. Potential to reverse years of age-related cartilage loss Tweet this We believe that any disease can be cured. - Remedium Bio